骨髓单个核细胞（bone marrow mononuclear cells, BMMNCs）在对急性脑梗死治疗中展示了潜在的应用前景。本课题组前期研究证实其中CXCR4(+)CD45(-)成分对急性脑梗死有明显的治疗作用，提示该细胞群可能是BMMNCs治疗脑梗死的主要功能成分。但其对慢性脑缺血作用尚无研究。本研究拟使用流式分选技术提取绿色转基因蛋白大鼠CXCR4(+)CD45(-)BMMNCs，静脉移植至改良的慢性脑缺血大鼠模型（m2VO），分析该细胞群在外周器官及缺血大脑的定向迁移情况；明确CXCR4(+)CD45(-) BMMNCs在缺血大脑中向不同类型细胞分化的情况，并研究其对局部微环境、脑血流、血管新生及长期神经功能预后的影响及机制；最后评价外源性VEGF能否提高CXCR4(+)CD45(-) BMMNCs治疗m2VO大鼠的疗效。该研究有助于发现治疗慢性脑缺血的新手段并提供依据。

Bone marrow mononuclear cells (BMMNCs) have represented a potential therapeutic value in the treatment of acute cerebral infarction and have received the extensive concerns of the academia. Our previous research revealed that CXCR4 (+) CD45 (-) subpopulation of BMMNCs could ameliorate the neurological symptoms of acute cerebral infarction significantly, Which indicated that CXCR4 (+) CD45 (-) BMMNCs subpopulation may play a dominant role in the BMMNCs therapy for the cerebral infarction. However, it is unclear if CXCR4 (+) CD45 (-) BMMNCs has similar effects in chronic cerebral hypoperfusion. In this study, we will firstly use CXCR4(+) CD45 (-) BMMNCs subpopulation as a cell-based therapy in chronic cerebral hypoperfusion, clarify the migration of the subpopulation in the ischemic brain and peripheral organs, evaluate their influences of cerebral blood flow and cognitive abilities on modified chronic cerebral hypoperfusion rat model (m2VO), furtherly extend relevant translational research and explore the cellular and molecular mechanisms. This study will help to represent a new therapeutic approach for chronic cerebral hypoperfusion and provide evidences for the treatment.